Markets

Biocon-backed Equillium files for a $86 million US IPO

Equillium, a Phase 1 biotech developing monoclonal antibody therapies for acute and chronic graft-versus-host disease and asthma, filed on Monday with the SEC to raise up to $86 million in an initial public offering.

The La Jolla, CA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol EQ. Equillium filed confidentially on August 3, 2018. Jefferies, Leerink Partners and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Biocon-backed Equillium files for a $86 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs